Targeting STPG4: A Potential Drug Asset (G285051)

Target Name: STPG4

NCBI ID: G285051

STPG4

Targeting STPG4: A Potential Drug Asset

Sperm-tail PG-rich repeat-containing protein 4 (STPG4) is a protein that is expressed in various tissues and cells in the human body. It is characterized by the presence of a unique repeat sequence at its C-terminus, which is composed of a glycine-rich repeat and a phosphorylated cysteine 鈥嬧?媟esidue.

The STPG4 protein is involved in a variety of cellular processes, including cell signaling, cell adhesion, and DNA replication. It is a key regulator of the stem-cell self-renewal cycle and has been implicated in the development and progression of various diseases, including cancer.

One of the unique features of STPG4 is its ability to interact with other proteins and molecules. It has been shown to interact with a variety of proteins, including the transcription factor PDGF-D, the protein kinase A1, and the transcription factor Nrf2. These interactions allow STPG4 to regulate the activity of these proteins and influence a wide range of cellular processes.

In addition to its role in cellular signaling, STPG4 is also of interest as a potential drug target. Its unique structure and interactions with other proteins make it an attractive target for small molecules and other therapeutic agents.

One approach to targeting STPG4 is to use small molecules to interfere with its activity. This can be done by binding to specific regions of the protein and disrupting its interactions with other molecules. This approach has been used to develop a variety of potential therapeutic compounds, including inhibitors of STPG4's activity that have been shown to be effective in preclinical studies.

Another approach to targeting STPG4 is to use antibodies to block its expression. This can be done by using antibodies that specifically recognize and bind to STPG4 and prevent it from being produced in the cells. This approach has been used to develop antibodies that have been shown to be effective in preclinical studies and clinical trials.

Overall, STPG4 is a protein that is of interest as a potential drug target. Its unique structure and interactions with other proteins make it an attractive target for small molecules and antibodies, and its involvement in cellular signaling makes it a potential candidate for treating a wide range of diseases. Further research is needed to fully understand the role of STPG4 and its potential as a drug target.

Protein Name: Sperm-tail PG-rich Repeat Containing 4

Functions: Maternal factor that plays a role in epigenetic chromatin reprogramming during early development of the zygote. Involved in the regulation of gametic DNA demethylation by inducing the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC)

The "STPG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STPG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets